Example 1: Uptake of tritiated testosterone

A pre-clinical study using the MetP technology for targeting the brain:

Compelling: The uptake of tritiated testosterone by the brain was about twice as high after intranasal administration as after intravenous administration.

Banks et al.: «About two-thirds of the testosterone entering the brain after i.n. [intranasal] administration did so by direct entry by nasal routes and the remainder indirectly by first entering the blood and then crossing the blood-brain barrier.»

Banks WA et al.; Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone; J Drug Target. 2009 Feb;17(2):91-7

Example 2: Amygdala activity

A clinical study using the MetP technology for targeting the human brain:

Consider the amygdala reactivity after a single nasal administration of testosterone.

1. Significant amygdala activity in the placebo condition of young women.
2. No significant amygdala activity in the placebo condition of middle-aged women.
3. Significant amygdala activity in middle-aged women after a single nasal administration of testosterone MetP.

Van Wingen et al.: «The middle-aged women received a single nasal dose of testosterone in a double-blind, placebo-controlled, crossover manner, which rapidly increased amygdala reactivity to a level comparable to the young women.»

van Wingen GA et al.;Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level; Neuropsychopharmacology. 2009 Feb;34(3):539-47

Constraints on a nasal drug delivery system

The development of a suitable nasal drug delivery system is challenging, due to:

• the anatomical and biological factors of the nasal cavity,
• the physicochemical properties of the drugs,
• the properties of the formulation,
• and the availability of a suitable application device to ensure that the drug is delivered to the target site in the nasal cavity.

Therefore, nose-to-brain delivery requires a perfect synergy of active ingredient, carrier formulation and nasal applicator.

This is, where MetP’s drug delivery platform fits in – it is fully developed, proven effective and safe, and furthermore it is extensively patent-protected.

The MetP’s nasal drug delivery system

Our MetP’s platform consists of a breakthrough formulation, an absolutely easy to use application device – and the possibility to serve mass market:

Silcum, our MetP's semi-solid gel matrix, is safe and versatile. Its formulation is perfectly adjusted to the anatomical and biological factors of the nasal cavity as well as easily adaptable to the physicochemical properties of a wide range of drugs: Silcum provides a slow elimination of drugs by mucociliary clearance and a tunable release of the drug.

Lecticula, our MetP’s single-dose nasal applicator, is, of course, properly tailored to the anatomical characteristics of the nose, yet flawlessly easy to handle, and even more: This mono-dose application device is 100 percent sterile and it delivers the exact dosage of the drug, completely independent from head position.

Maxima, our efficient filling technology, allows to serve mass market and to produce pilot samples.

Our MetP’s platform for nasal drug application is proven effective and suitable for a wide range of substances, providing overwhelming benefits, both clinical and competitive – perhaps also for your substance or molecule.